Neumora Therapeutics Confirms Nasdaq Listing for NMRA Stock

Ticker: NMRA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1885522

Neumora Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyNeumora Therapeutics, INC. (NMRA)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance

TL;DR

**NMRA confirms Nasdaq listing, business as usual.**

AI Summary

Neumora Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose that its common stock, with a $0.0001 par value per share, is registered on The Nasdaq Global Select Market under the trading symbol NMRA. This filing is a routine update, confirming the company's listing and compliance with SEC regulations. For investors, this matters because it reaffirms Neumora's status as a publicly traded company on a major exchange, ensuring liquidity and transparency for their shares.

Why It Matters

This filing confirms Neumora Therapeutics' continued listing on a major stock exchange, which is crucial for investor confidence and the liquidity of its shares.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not indicate any new financial or operational risks for Neumora Therapeutics.

Analyst Insight

This filing is administrative and does not provide new information that would warrant immediate action. Investors should continue to monitor Neumora Therapeutics for operational updates, clinical trial results, or financial performance reports.

Key Numbers

Key Players & Entities

FAQ

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant as specified in its charter is NEUMORA THERAPEUTICS, INC.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024.

What is the trading symbol for Neumora Therapeutics, Inc. common stock?

The trading symbol for Neumora Therapeutics, Inc. common stock is NMRA.

On which exchange is Neumora Therapeutics, Inc. common stock registered?

Neumora Therapeutics, Inc. common stock is registered on The Nasdaq Global Select Market.

What is the par value per share for Neumora Therapeutics, Inc. common stock?

The par value per share for Neumora Therapeutics, Inc. common stock is $0.0001.

Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-01-08 08:32:58

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Neumora Therapeutics, Inc. (the "Company") made available a corporate presentation, which it plans to use for meetings with investors and analysts at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the presentation is being furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Corporate Presentation dated January 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUMORA THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ Joshua Pinto Joshua Pinto Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing